LMR Master Fund’s Alaunos Therapeutics TCRT Stock Holding History

LMR Master Fund’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-375	Closed	-$118K	–	415
2013 Q2	$118K	Buy	+375	New	+$104K	0.01%	404

Other funds holding TCRT

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

LMR Master Fund's TCRT Position: Q3 2013 in Review

LMR Master Fund sold out of Alaunos Therapeutics (TCRT) in Q3 2013, closing a stake of 375 shares — an estimated $118K sold.

LMR Master Fund first reported a position in TCRT in Q2 2013 and held it in 1 quarter. The position peaked at $118K in Q2 2013. 77 funds tracked by Wall St. Rank hold TCRT as of Q3 2013.

LMR Master Fund reported no remaining Alaunos Therapeutics position as of Q3 2013 after selling out during the quarter.
LMR Master Fund sold 375 Alaunos Therapeutics shares in Q3 2013, an estimated $118K.
LMR Master Fund first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 1 quarter.
LMR Master Fund's Alaunos Therapeutics position peaked at $118K in Q2 2013.
77 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2013.

Based on LMR Master Fund's 13F filing for Q3 2013, filed 14 Nov 2013.